Aspirin Activation of Eosinophils and Mast Cells: Implications in the Pathogenesis of Aspirin-Exacerbated Respiratory Disease

John W. Steinke, Julie Negri, Lixia Liu, Spencer C. Payne and Larry Borish

*J Immunol* 2014; 193:41-47; Prepublished online 2 June 2014;
doi: 10.4049/jimmunol.1301753
http://www.jimmunol.org/content/193/1/41

**References**  This article cites 37 articles, 8 of which you can access for free at: http://www.jimmunol.org/content/193/1/41.full#ref-list-1

**Subscription**  Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

**Permissions**  Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**  Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Aspirin Activation of Eosinophils and Mast Cells: Implications in the Pathogenesis of Aspirin-Exacerbated Respiratory Disease


Reactions to aspirin and nonsteroidal anti-inflammatory drugs in patients with aspirin-exacerbated respiratory disease (AERD) are triggered when constraints upon activated eosinophils, normally supplied by PGE2, are removed secondary to cyclooxygenase-1 inhibition. However, the mechanism driving the concomitant cellular activation is unknown. We investigated the capacity of aspirin itself to provide this activation signal. Eosinophils were enriched from peripheral blood samples and activated with lysine ASA (LysASA). Parallel samples were stimulated with related nonsteroidal anti-inflammatory drugs. Activation was evaluated as Ca2+ flux, secretion of cysteinyl leukotrienes (CysLTs), and eosinophil-derived neurotoxin (EDN) release. CD34+ progenitor-derived mast cells were also used to test the influence of aspirin on human mast cells with measurements of Ca2+ flux and PGD2 release. LysASA induced Ca2+ fluxes and EDN release, but not CysLT secretion from circulating eosinophils. There was no difference in the sensitivity or extent of activation between AERD and control subjects, and sodium salicylate was without effect. Like eosinophils, aspirin was able to activate human mast cells directly through Ca2+ flux and PGD2 release. AERD is associated with eosinophils maturing locally in a high IFN-γ milieu. As such, in additional studies, eosinophil progenitors were differentiated in the presence of IFN-γ prior to activation with aspirin. Eosinophils matured in the presence of IFN-γ displayed robust secretion of both EDN and CysLTs. These studies identify aspirin as the trigger of eosinophil and mast cell activation in AERD, acting in synergy with its ability to release cells from the anti-inflammatory constraints of PGE2. The Journal of Immunology, 2014, 193: 41–47.

A spri

Copyright © 2014 by The American Association of Immunologists, Inc. 0022-1767/14$16.00

www.jimmunol.org/cgi/doi/10.4049/jimmunol.1301753

Received for publication July 2, 2013. Accepted for publication May 3, 2014.

This work was supported by National Institutes of Health Grants R01-AI47737 and P01-A150989.

*Address correspondence and reprint requests to Dr. Larry Borish, Asthma and Allergic Disease Center, Box 801355, Charlottesville, VA 22903. E-mail address: lb4m@virginia.edu

†Asthma and Allergic Disease Center, Department of Medicine, University of Virginia Health System, Charlottesville, VA 22908; †Carter Immunology Center, University of Virginia Health System, Charlottesville, VA 22908; and ‡Department of Otolaryngology–Head and Neck Surgery, University of Virginia Health System, Charlottesville, VA 22908.

Abbreviations used in this article: AERD, aspirin-exacerbated respiratory disease; COX, cyclooxygenase; CysLT, cysteinyl leukotriene; EDN, eosinophil-derived neurotoxin; EGTA, ethylene glycol-bis[N,N'-tetraacetic acid; LTC4S, leukotriene C4 synthase; LysASA, lysine aspirin; NaSal, sodium salicylate; NSAID, nonsteroidal anti-inflammatory drug; SCF, stem cell factor.

Copyright © 2014 by The American Association of Immunologists, Inc. 0022-1767/14$16.00

This work was supported by National Institutes of Health Grants R01-AI47737 and P01-A150989.

Received for publication July 2, 2013. Accepted for publication May 3, 2014.

*Address correspondence and reprint requests to Dr. Larry Borish, Asthma and Allergic Disease Center, Box 801355, Charlottesville, VA 22903. E-mail address: lb4m@virginia.edu

†Asthma and Allergic Disease Center, Department of Medicine, University of Virginia Health System, Charlottesville, VA 22908; †Carter Immunology Center, University of Virginia Health System, Charlottesville, VA 22908; and ‡Department of Otolaryngology–Head and Neck Surgery, University of Virginia Health System, Charlottesville, VA 22908.

Abbreviations used in this article: AERD, aspirin-exacerbated respiratory disease; COX, cyclooxygenase; CysLT, cysteinyl leukotriene; EDN, eosinophil-derived neurotoxin; EGTA, ethylene glycol-bis[N,N'-tetraacetic acid; LTC4S, leukotriene C4 synthase; LysASA, lysine aspirin; NaSal, sodium salicylate; NSAID, nonsteroidal anti-inflammatory drug; SCF, stem cell factor.

Copyright © 2014 by The American Association of Immunologists, Inc. 0022-1767/14$16.00

This work was supported by National Institutes of Health Grants R01-AI47737 and P01-A150989.

Received for publication July 2, 2013. Accepted for publication May 3, 2014.

*Address correspondence and reprint requests to Dr. Larry Borish, Asthma and Allergic Disease Center, Box 801355, Charlottesville, VA 22903. E-mail address: lb4m@virginia.edu

†Asthma and Allergic Disease Center, Department of Medicine, University of Virginia Health System, Charlottesville, VA 22908; †Carter Immunology Center, University of Virginia Health System, Charlottesville, VA 22908; and ‡Department of Otolaryngology–Head and Neck Surgery, University of Virginia Health System, Charlottesville, VA 22908.

Abbreviations used in this article: AERD, aspirin-exacerbated respiratory disease; COX, cyclooxygenase; CysLT, cysteinyl leukotriene; EDN, eosinophil-derived neurotoxin; EGTA, ethylene glycol-bis[N,N'-tetraacetic acid; LTC4S, leukotriene C4 synthase; LysASA, lysine aspirin; NaSal, sodium salicylate; NSAID, nonsteroidal anti-inflammatory drug; SCF, stem cell factor.

Copyright © 2014 by The American Association of Immunologists, Inc. 0022-1767/14$16.00

This work was supported by National Institutes of Health Grants R01-AI47737 and P01-A150989.

Received for publication July 2, 2013. Accepted for publication May 3, 2014.

*Address correspondence and reprint requests to Dr. Larry Borish, Asthma and Allergic Disease Center, Box 801355, Charlottesville, VA 22903. E-mail address: lb4m@virginia.edu

†Asthma and Allergic Disease Center, Department of Medicine, University of Virginia Health System, Charlottesville, VA 22908; †Carter Immunology Center, University of Virginia Health System, Charlottesville, VA 22908; and ‡Department of Otolaryngology–Head and Neck Surgery, University of Virginia Health System, Charlottesville, VA 22908.

Abbreviations used in this article: AERD, aspirin-exacerbated respiratory disease; COX, cyclooxygenase; CysLT, cysteinyl leukotriene; EDN, eosinophil-derived neurotoxin; EGTA, ethylene glycol-bis[N,N'-tetraacetic acid; LTC4S, leukotriene C4 synthase; LysASA, lysine aspirin; NaSal, sodium salicylate; NSAID, nonsteroidal anti-inflammatory drug; SCF, stem cell factor.

Copyright © 2014 by The American Association of Immunologists, Inc. 0022-1767/14$16.00

This work was supported by National Institutes of Health Grants R01-AI47737 and P01-A150989.

Received for publication July 2, 2013. Accepted for publication May 3, 2014.

*Address correspondence and reprint requests to Dr. Larry Borish, Asthma and Allergic Disease Center, Box 801355, Charlottesville, VA 22903. E-mail address: lb4m@virginia.edu

†Asthma and Allergic Disease Center, Department of Medicine, University of Virginia Health System, Charlottesville, VA 22908; †Carter Immunology Center, University of Virginia Health System, Charlottesville, VA 22908; and ‡Department of Otolaryngology–Head and Neck Surgery, University of Virginia Health System, Charlottesville, VA 22908.

Abbreviations used in this article: AERD, aspirin-exacerbated respiratory disease; COX, cyclooxygenase; CysLT, cysteinyl leukotriene; EDN, eosinophil-derived neurotoxin; EGTA, ethylene glycol-bis[N,N'-tetraacetic acid; LTC4S, leukotriene C4 synthase; LysASA, lysine aspirin; NaSal, sodium salicylate; NSAID, nonsteroidal anti-inflammatory drug; SCF, stem cell factor.

Copyright © 2014 by The American Association of Immunologists, Inc. 0022-1767/14$16.00

This work was supported by National Institutes of Health Grants R01-AI47737 and P01-A150989.

Received for publication July 2, 2013. Accepted for publication May 3, 2014.

*Address correspondence and reprint requests to Dr. Larry Borish, Asthma and Allergic Disease Center, Box 801355, Charlottesville, VA 22903. E-mail address: lb4m@virginia.edu

†Asthma and Allergic Disease Center, Department of Medicine, University of Virginia Health System, Charlottesville, VA 22908; †Carter Immunology Center, University of Virginia Health System, Charlottesville, VA 22908; and ‡Department of Otolaryngology–Head and Neck Surgery, University of Virginia Health System, Charlottesville, VA 22908.

Abbreviations used in this article: AERD, aspirin-exacerbated respiratory disease; COX, cyclooxygenase; CysLT, cysteinyl leukotriene; EDN, eosinophil-derived neurotoxin; EGTA, ethylene glycol-bis[N,N'-tetraacetic acid; LTC4S, leukotriene C4 synthase; LysASA, lysine aspirin; NaSal, sodium salicylate; NSAID, nonsteroidal anti-inflammatory drug; SCF, stem cell factor.

Copyright © 2014 by The American Association of Immunologists, Inc. 0022-1767/14$16.00

This work was supported by National Institutes of Health Grants R01-AI47737 and P01-A150989.
Although the defining infiltration of eosinophils suggests a Th2 cytokine milieu, our recent studies demonstrated that AERD is also characterized by the expression of IFN-γ and that the eosinophils themselves are the primary source of this cytokine (17). Significantly, we demonstrated that among the classic signature Th1 and Th2 cytokines, only IFN-γ was able to upregulate LTC₄S in eosinophils developing from hematopoietic progenitor cells, a feature not shared with IL-4, IL-5, IL-13, or GM-CSF (17). As upregulated LTC₄S in AERD is primarily a feature of sinonasal and lung—but not circulating—eosinophils (8, 15; J.W. Steinke and L. Borish, unpublished observations), we argued that this was a feature of eosinophils differentiating locally in the airway from the exuberant population of infiltrating precursors (CD34⁺IL-5Ra⁺ cells) (18, 19).

The current studies were therefore designed to assess direct activation of eosinophils and mast cells by aspirin and other NSAIDs through one of the off-target pathways ascribed to them (20, 21). In addition, we investigated the capacity of IFN-γ to license the ability of newly differentiated eosinophils to respond to aspirin (and other NSAIDs) with CysLT release.

Materials and Methods

Subjects

The study was approved by the University of Virginia Institutional Review Board for Health Science Research, and all subjects gave their informed consent. Subjects with and without AERD were recruited for this study. AERD was diagnosed based upon clinical criteria and was defined by the presence of asthma and at least one hypersensitivity reaction, including urticaria, nasal congestion, or shortness of breath within 2–3 h of ingestion of either aspirin or another nonsteroidal anti-inflammatory drug.

Reagents

Ketorolac was purchased from Hospira (Lake Forest, IL), sodium salicylate (NaSal) from Acros Organics (Geel, Belgium), lysine aspirin (LysASA) from Sanofi-Aventis (Athens, Greece), and celecoxib from Pfizer (New York).

Cell culture

PBMCs were isolated through Ficoll-Hypaque (Sigma-Aldrich, St Louis, MO) density centrifugation from blood obtained from subjects enrolled in the study. Eosinophils were enriched from granulocytes using negative magnetic affinity column purification (Miltenyi Biotec), and eosinophil progenitors were derived using the technique of Hudson et al. (22) by culturing purified CD34⁺ cells in complete medium (RPMI 1640 and 10% FBS) supplemented with stem cell factor (SCF) 25 ng/ml; BD Biosciences), thymopoietin (25 ng/ml; R&D Systems, Minneapolis, MN), Fms-like tyrosine kinase 3 ligand (25 ng/ml; BD Biosciences), IL-3 (25 ng/ml) with or without IFN-γ (20 ng/ml; BD Biosciences) for 3 d and then cultured for an additional 3 wk with just IL-3 and IL-5 (±IFN-γ). Cells were washed, and fresh media and cytokines were applied weekly. Maturation was assessed as previously described (17), and cells were activated as described above.

Mast cells. For studies involving mast cells, CD34⁺ cells isolated as described were cultured for 8 wk with SCF and IL-6 and, for the first week only, with IL-3 according to the methodology of Kirshenbaum et al. (23, 24).

Statistical analyses

Data were contrasted between unstimulated and stimulated cells by the Wilcoxon rank sum test for nonparametric data analyses or paired t test for parametric data. Normal and AERD cohorts were compared using unpaired t tests. Statistical analyses were performed using GraphPad Prism 6.

Results

Eosinophil Ca²⁺ flux

We evaluated the capacity of aspirin and other NSAIDs to directly activate enriched peripheral blood eosinophils, initially by examining induction of calcium fluxes. For these studies, we used the aspirin-like compound LysASA, which retains the biological properties of aspirin while being water soluble. Ca²⁺ fluxes were consistently observed at physiologically relevant concentrations for eosinophils in a dose-dependent manner [p < 0.05; data from 12 subjects (6 each with and without AERD) are displayed in Fig. 1]. The presence of AERD made no statistically significant difference in either the extent of Ca²⁺ mobilization with eosinophils induced by aspirin but does not inhibit COX, and ketorolac, which is a nonselective COX inhibitor. Unlike LysASA, both NaSal and unexpectedly—ketoconazole were unable to induce calcium flux (Fig. 2A). To determine whether the calcium mobilized in the assay was derived from intracellular stores, additional studies were performed in the presence of EGTA. Insignificant decreases in Ca²⁺ flux were observed (Fig. 2B), suggesting that the main source of calcium was being derived from intracellular stores.

Eosinophil degradation

To investigate whether NSAID stimulation would lead to release of eosinophil-derived mediators, EDN and CysLT secretion was assessed. Incubation with LysASA in a dose-dependent fashion resulted in statistically significant increases of EDN secretion (p < 0.05) (Fig. 3). As with the Ca²⁺ flux, no differences were observed between AERD and control cohorts (data not shown). Further, no EDN release was observed after incubation with NaSal or ketorolac. However, incubation with celecoxib did result in release of EDN (p < 0.01) at the 3 and 10 mM concentrations, although not as robust a release as with LysASA (Fig. 3). In contrast to the average of the three measurements used for analysis. ATP (300 μM) was used as a positive control. Data analyses were performed using GraphPad Prism 6 (GraphPad Software, San Diego, CA). Additional studies were performed in the additional presence of ethylene glycol-bis(β-aminoethyl ester)-N,N',N'_,N'_'-tetraacetic acid (EGTA), 1 mM, to chelate extracellular sources of Ca²⁺.
EDN results, LysASA did not increase CysLT secretion from these peripheral blood-derived eosinophils, again, even when obtained from AERD subjects (data not shown).

**Influence of IFN-γ on aspirin activation of eosinophils derived from CD34+ progenitors**

Circulating eosinophils display comparatively modest expression of LTC₄S, even when derived from AERD subjects, compared with what is observed in their sinonasal tissue and lungs (8, 15; J.W. Steinke and L. Borish, unpublished observations). However, we have recently demonstrated that eosinophils matured in the additional presence of IFN-γ—as occurs locally in the sinonasal tissue and lungs of AERD patients—display upregulated LTC₄S expression and markedly increased their release of CysLTs (and EDN) when activated with PMA/ionomycin (17). We therefore queried whether eosinophils differentiated from CD34+ hematopoietic progenitor cells in the presence of IFN-γ would demonstrate CysLT secretion when exposed to LysASA. As with eosinophils obtained from circulating blood, eosinophils differentiated in the absence of IFN-γ (n = 6) secreted EDN after exposure to LysASA (Fig. 4A), but only modest secretion of CysLTs was observed (Fig. 4B). The presence of IFN-γ during maturation significantly enhanced the capacity of in vitro differentiated eosinophils to degranulate and release EDN (Fig. 4A; p < 0.0004 at the 1 and 10 mM concentrations). More...
importantly, the concomitant presence of IFN-γ led to significant induction of the capacity of these eosinophils to secrete CysLTs (Fig. 4B; \( p < 0.03 \) at the 1 and 10 mM concentrations).

*Ketorolac activation*

AERD subjects react to aspirin and other nonselective NSAIDs, including ketorolac (25, 26). We therefore interrogated the ability of this compound to activate CD34\(^+\) progenitor–derived eosinophils and, as with LysASA, observed significant CysLT release (Fig. 4B). The activation induced by ketorolac at the 10 mM concentration was more pronounced than that observed with LysASA (\( p < 0.002 \)) and, as displayed in Fig. 4A, was further enhanced when the cells were matured with IFN-γ.

Aspirin activation of CD34\(^+\) progenitor-derived mast cells

Having demonstrated aspirin activation of eosinophils, we wanted to address whether similar activation pathways were induced in mast cells. As with eosinophils, we initially investigated the capacity of these compounds to drive Ca\(^{2+}\) fluxes in mast cells differentiated from CD34\(^+\) progenitor cells. Similar to the results for eosinophils, LysASA was able to significantly (\( p < 0.05 \)) stimulate Ca\(^{2+}\) flux (Fig. 5A). Although ketorolac induced modest Ca\(^{2+}\) fluxes, the results were not significantly different from those with unstimulated cells (Fig. 5A). Because aspirin/NSAID reactions in AERD are associated with PGD\(_2\) release, PGD\(_2\) secretion was measured after CD34\(^+\)-derived mast cells were stimulated with LysASA. Similar to the Ca\(^{2+}\) flux data, PGD\(_2\)
release was observed at the highest concentration of LysASA (Fig. 5B; p < 0.05).

Discussion
AERD is characterized by eosinophilic infiltration into the upper (sinus and nasal polyp) and lower (bronchial) airway that is markedly greater than that observed in aspirin-tolerant asthmatics (13–15), and these eosinophils are individually characterized by much higher expression of the rate-limiting enzyme permitting CysLT synthesis, LTC4S (8). As a result, when eosinophils are activated after ingestion of aspirin or other nonselective inhibitors of COX, a surge in CysLT secretion occurs (27, 28). CysLT secretion is further enhanced by the distinct tendency of platelets to adhere to eosinophils and neutrophils in AERD and the transcellular conversion of LTA4 into CysLTs by the platelets (10). CysLTs underlie much of the symptomatic component of these anaphylactoid reactions, as demonstrated by the ability of leukotriene modifiers to greatly attenuate their presence and severity (15, 29, 30). Although many cell types are capable and likely contribute to the CysLT production and inflammatory response in AERD, these studies focused on the contribution of these products by eosinophils and mast cells.

The stimulus driving eosinophil and mast cell activation is not known. In part, these reactions reflect the ability of PGE2 acting through the anti-inflammatory receptor EP2 to constrain cellular activation. Thus, coadministration of synthetic PGE2 prevents the bronchospastic response to aspirin challenge (6). This explanation, however, is incomplete. If a low PGE2 milieu were the only condition required for eosinophil activation to occur, then eosinophil activation would also occur in all asthmatics and even in nonasthmatics, albeit in the relative absence of CysLT production, LTC4S (8). As a result, when eosinophils are activated after ingestion of aspirin or other nonselective inhibitors of COX, a surge in CysLT secretion occurs (27, 28). CysLT secretion is further enhanced by the distinct tendency of platelets to adhere to eosinophils and neutrophils in AERD and the transcellular conversion of LTA4 into CysLTs by the platelets (10). CysLTs underlie much of the symptomatic component of these anaphylactoid reactions, as demonstrated by the ability of leukotriene modifiers to greatly attenuate their presence and severity (15, 29, 30). Although many cell types are capable and likely contribute to the CysLT production and inflammatory response in AERD, these studies focused on the contribution of these products by eosinophils and mast cells.

The stimulus driving eosinophil and mast cell activation is not known. In part, these reactions reflect the ability of PGE2 acting through the anti-inflammatory receptor EP2 to constrain cellular activation. Thus, coadministration of synthetic PGE2 prevents the bronchospastic response to aspirin challenge (6). This explanation, however, is incomplete. If a low PGE2 milieu were the only condition required for eosinophil activation to occur, then eosinophil activation would also occur in all asthmatics and even in nonasthmatics, albeit in the relative absence of CysLT generation. This observation suggests the concomitant need for a positive signal driving eosinophil activation. Aspirin and other NSAIDs have numerous off-target effects, independent of their ability to inhibit COX (20). Recently, as an example, aspirin was demonstrated to engage an l-type Ca2+ channel to promote cellular activation (21). We therefore postulated that aspirin itself is responsible for cellular activation in AERD.

With the use of peripheral blood eosinophils, induction of Ca2+ flux was measured following stimulation with LysASA (Fig. 1). In a dose-dependent manner, LysASA generated a Ca2+ flux, with a maximal response observed at 10 mM, but significant changes also observed at pharmacologically meaningful concentrations. When aspirin-tolerant and aspirin-sensitive circulating eosinophils were compared, no difference was found in their responses to LysASA stimulation. Similar results were observed when we examined EDN secretion in response to LysASA (Fig. 3). However, in addition to observing activation with control subjects, many other features of this LysASA-induced activation of circulating eosinophils were inconsistent with what is observed in AERD subjects, including especially the absence of CysLT production, but also the failure to observe activation with ketorolac.

This induction of Ca2+ fluxes and EDN secretion by LysASA acting on eosinophils derived from control subjects was unexpected. Numerous potential explanations exist for the failure to observe—even modest—hypersensitivity reactions in aspirin-tolerant asthmatics and healthy controls. To some extent, this reflects the relative dearth of eosinophils in these other conditions with several studies, including ours (13, 15), demonstrating >10-fold fewer tissue eosinophils, and as such, the impact of eosinophil activation would be proportionately less. However, the more likely explanation is the relative impact of COX inhibitors in these conditions. PGE2 acts through the anti-inflammatory EP2 receptor to mediate its protective responses (6, 31). In AERD, the PGE2 synthetic pathway is suppressed, and both constitutive tissue PGE2 concentrations and expression of the anti-inflammatory PGE2 receptor EP2 are diminished (15, 32, 33). Thus, AERD patients exist on the precipice of cellular activation with their borderline expression of PGE2 and EP2 such that even a modest decrease in PGE2 can have the observed catastrophic effects. This model is consistent with recent observations that in a murine model of AERD, knockout of the rate-limiting enzyme responsible for PGE2 synthesis, specifically murine PGES-1, renders these mice susceptible to anaphylactoid reactions after exposure to aspirin (34).

A further explanation for lack of reactivity in control cohorts is that a large component of the syndrome induced by aspirin is driven...
by CysLTs, as shown by the ability of LT modifiers to greatly attenuate the severity of reactions (29, 35). Of interest, we did not observe CysLT secretion from eosinophils even when derived from the circulation of AERD subjects. We recently demonstrated that AERD is characterized by a high tissue IFN-γ milieu and, in contrast to the Th2 signature cytokines (IL-3, IL-4, IL-5, IL-13, and GM-CSF), IFN-γ was uniquely capable of driving the expression of LTC4S and the secretion of CysLTs from eosinophils differentiated from CD34+ hematopoietic progenitor cells (17). AERD sinonasal and lung tissue is characterized by high numbers of eosinophilic hematopoietic progenitor (CD34+IL-5Rα+) cells (18, 19) that will mature in this presence of IFN-γ and acquire the ability to produce CysLTs; this observation would suggest that the robust CysLT production would be limited to airway—and not circulating—eosinophils. In the current studies, we therefore investigated whether eosinophils differentiated from progenitor cells in the presence of IFN-γ would recapitulate the sensitivity to aspirin displayed by tissue eosinophils in vivo in AERD. Not only was EDN release increased in IFN-γ–stimulated eosinophil progenitors (Fig. 4A), but consistent with their increased LTC4S expression, CysLT secretion was thereby also detected upon LysASA activation (Fig. 4B). Importantly, activation was again also significant at lower, pharmacologically relevant, concentrations of LysASA.

Having observed activation by LysASA, we tested the ability of other NSAIDs to activate eosinophils. The absence of effects by NaSal on eosinophils on both Ca2+ flux (Fig. 2A) and EDN release (Fig. 3) indicates that the action by LysASA is not being mediated by the salicylate component (20), a result consistent with the ability of AERD patients to tolerate salicylates (36). In contrast, AERD patients are variably sensitive to nonselective NSAIDs, capable of expression of IFN-γ, driven by LysASA (Fig. 4A), and acquire leukotriene overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur. Respir. J. 6: 391–399.


